Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Water Concentration 4 Clear all
Completed Not applicable Interventional Results available

Monitoring and Predicting Chemotherapy Response Using DOSI

NCT01217385
View directory record Official record
Conditions
Breast Cancer
Interventions
DOSI
Procedure
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Irvine, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Third Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

NCT07726238
View directory record Official record
Conditions
Body Odor
Interventions
NOBO postbiotic, Placebo
Other
Lead sponsor
Kingdom
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CommitFit App to Facilitate Health Behavior Change in Clinic Adolescents

NCT06985251
View directory record Official record
Conditions
Overweight Adolescents
Interventions
gamified mHealth lifestyle app, Attention Control, gamified mHealth app with financial incentives
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
13 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
paclitaxel, TAK-228, TAK-117
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 27, 2026, 1:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

NCT00801931
View directory record Official record
Conditions
Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions
Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

NCT01369303
View directory record Official record
Conditions
Prevention
Interventions
Tenofovir 1% vaginal gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Sep 27, 2026, 1:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents

NCT07223151
View directory record Official record
Conditions
Obesity, Adolescent, Dietary Sugars, Taste Perception, Insulin Resistance, Feeding Behavior
Interventions
Unsweetened Sparkling Water Replacement, Progressively Reduced Sugar Beverage Replacement, Plain Water Replacement
Behavioral
Lead sponsor
Nana Gletsu Miller
Other
Eligibility
12 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Bloomington, Indiana • Indianapolis, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety of QRH-882260 Heptapeptide

NCT02574858
View directory record Official record
Conditions
Healthy Adults
Interventions
QRH-882260
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 27, 2026, 1:28 AM EDT
Recruiting Phase 2 Interventional

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007
View directory record Official record
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Real-world Evaluation of JBA GlucoTrojan With Reducose® on Glycemic Response

NCT06509204
View directory record Official record
Conditions
Food Habits
Interventions
Glucotrojan
Dietary Supplement
Lead sponsor
Tastermonial Inc
Industry
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cupertino, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel

NCT01306331
View directory record Official record
Conditions
Contraception
Interventions
Conceptrol, Amphora
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
3,389 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 27, 2026, 1:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural and Psychological Mechanisms of Pain Perception

NCT02446262
View directory record Official record
Conditions
Pain, Normal Physiology, Healthy Volunteers
Interventions
Instructions, Attention, Thermal Pain, Placebo instructions
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 3 Interventional

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

NCT04786873
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Macimorelin, Arginine, Clonidine
Drug · Diagnostic Test
Lead sponsor
AEterna Zentaris
Industry
Eligibility
2 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 27, 2026, 1:28 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

NCT04058132
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
Drug · Device · Other + 1 more
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Results available

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

NCT04249076
View directory record Official record
Conditions
Cataract
Interventions
Clobetasol Propionate, Vehicle
Drug
Lead sponsor
Salvat
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Sun City, Arizona • Hemet, California • Inglewood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

NCT02597777
View directory record Official record
Conditions
Oily Skin
Interventions
Acetyl Hexapeptide-8, Placebo vehicle
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following Multiple Application Times

NCT04235985
View directory record Official record
Conditions
General Skin Cleansing
Interventions
Chlorhexidine Gluconate with HUBS
Combination Product
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 27, 2026, 1:28 AM EDT
Not yet recruiting Phase 4 Interventional

Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study

NCT04200729
View directory record Official record
Conditions
Acute, Perforated Appendicitis
Interventions
Irrigation with PVI, Usual care
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
2 Years to 17 Years
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessing NOS Uptake With PET Imaging in Lung Inflammation

NCT02151552
View directory record Official record
Conditions
Lung Inflammation
Interventions
Endotoxin (E. coli O:113, Reference Endotoxin), [18F](+/-)NOS
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fluid Volume During Fluid Shifts

NCT03447574
View directory record Official record
Conditions
Development of Non-invasive Protocol
Interventions
ethanol dilution
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 27, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 27, 2026, 1:28 AM EDT